Endometrial Carcinoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Endometrial Carcinoma Market Outlook

Thelansis’s “Endometrial Carcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endometrial Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Endometrial Carcinoma Overview

Endometrial carcinoma is a cancer that affects the lining of the uterus (endometrium) in younger women. It is estrogen-dependent and characterized by a defined precursor lesion called endometrial intraepithelial neoplasia (EIN). The pathogenesis is believed to begin with uninterrupted endometrial proliferation stimulated by estrogen, which progresses through various stages of endometrial hyperplasia. Lead to the development of EIN, which can transform into endometrioid carcinoma. It can be characterized by stromal and myometrial invasion, mutations in certain genes (PTEN and KRAS2), microsatellite instability caused by mismatch repair defects, and a near-diploid karyotype. The tumor also usually expresses estrogen and progesterone receptors (ER and PR). The natural history of endometrial carcinomas is that they begin as preinvasive intraepithelial lesions, which then progress to invasive cancers involving the endometrial stroma and then penetrating deeper into the myometrium. Lead to the spread of cancer through lymphatic channels to regional lymph nodes, from which it can metastasize to other body parts. The International Federation of Gynecology and Obstetrics (FIGO) classifies endometrial endometrioid carcinomas into three grades (Grade I, Grade II, and Grade III) based on the percentage of solid non-squamous growth patterns. The prognosis for patients with endometrial cancer depends on various factors, including the extent of the disease, histotype, size, grade, and co-morbidities.

• The prevalence of endometrial cancer in the United States is 25.7/per 100,000 women per year. The lifetime risk for developing this disease is approximately 2.8% in American women.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: